{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:39:16Z","timestamp":1792157956178,"version":"4.4.0"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"48","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation"},{"DOI":"10.13039\/501100012524","name":"Dutch Federation of University Medical Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"the Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Royal Netherlands Academy of Sciences for the GENIUS-II"},{"name":"Netherlands Organization for Scientific Research"},{"DOI":"10.13039\/501100003246","name":"NWO","doi-asserted-by":"publisher","award":["016.130.676"],"award-info":[{"award-number":["016.130.676"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["H2020-PHC-2015-667673"],"award-info":[{"award-number":["H2020-PHC-2015-667673"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["CD40-INN 681492"],"award-info":[{"award-number":["CD40-INN 681492"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","award":["692511"],"award-info":[{"award-number":["692511"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Centre for Cardiovascular Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1\u03b2 antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.<\/jats:p>\n               <jats:p\/>","DOI":"10.1093\/eurheartj\/ehz283","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T19:11:32Z","timestamp":1555528292000},"page":"3937-3946","source":"Crossref","is-referenced-by-count":185,"title":["Immunotherapy for cardiovascular disease"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-5744","authenticated-orcid":false,"given":"Esther","family":"Lutgens","sequence":"first","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"Department of Medical Biochemistry, Amsterdam University Medical Centers, Location AMC, Amsterdam Cardiovascular Sciences (ACS), University of Amsterdam , Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Atzler","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"Department of Medical Biochemistry, Amsterdam University Medical Centers, Location AMC, Amsterdam Cardiovascular Sciences (ACS), University of Amsterdam , Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"},{"name":"Walther-Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universit\u00e4t , Goethestra\u00dfe 33, Munich 80336, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"D\u00f6ring","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Duchene","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Steffens","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-8714","authenticated-orcid":false,"given":"Christian","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Prevention (IPEK), CRC 1123 Atherosclerosis \u2013 Mechanisms and Networks of novel therapeutic Targets, Ludwig-Maximilians-Universit\u00e4t, Ludwig-Maximilians-University Munich , Pettenkoferstra\u00dfe 9, Munich 80336, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich, Germany"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , Universiteitsingel 50, 6229 ER Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"2022102609351097300_ehz283-B1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2022102609351097300_ehz283-B3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/CIRCRESAHA.115.306427","article-title":"Adaptive response of T and B cells in atherosclerosis","volume":"118","author":"Ketelhuth","year":"2016","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCRESAHA.115.306256","article-title":"Macrophage phenotype and function in different stages of atherosclerosis","volume":"118","author":"Tabas","year":"2016","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/CIRCRESAHA.118.313816","article-title":"Atherosclerosis","volume":"123","author":"Kobiyama","year":"2018","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B6","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1007\/s00018-013-1289-1","article-title":"Inflammation and immune system interactions in atherosclerosis","volume":"70","author":"Legein","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"2022102609351097300_ehz283-B7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.117.312513","article-title":"Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry","volume":"122","author":"Winkels","year":"2018","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cvr\/cvy109","article-title":"Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity","volume":"114","author":"Cole","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2022102609351097300_ehz283-B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology","volume":"115","author":"Tu\u00f1\u00f3n","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2022102609351097300_ehz283-B10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/eurheartj\/ehv236","article-title":"Novel methodologies for biomarker discovery in atherosclerosis","volume":"36","author":"Hoefer","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102609351097300_ehz283-B11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102609351097300_ehz283-B12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102609351097300_ehz283-B13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102609351097300_ehz283-B14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"2022102609351097300_ehz283-B15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2022102609351097300_ehz283-B16","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102609351097300_ehz283-B17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/CIRCRESAHA.117.311984","article-title":"CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting","volume":"121","author":"Weber","year":"2017","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1\u03b2 has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102609351097300_ehz283-B20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.297.1.43","article-title":"Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial","volume":"297","author":"Armstrong","year":"2007","journal-title":"JAMA"},{"key":"2022102609351097300_ehz283-B21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial","volume":"315","author":"O\u2019Donoghue","year":"2016","journal-title":"JAMA"},{"key":"2022102609351097300_ehz283-B22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B23","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B24","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","article-title":"Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial","volume":"371","author":"Torre-Amione","year":"2008","journal-title":"Lancet"},{"key":"2022102609351097300_ehz283-B26","first-page":"3224.","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"99","author":"Everett","year":"2018","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCULATIONAHA.118.036065","article-title":"Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy","volume":"139","author":"Bansal","year":"2019","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"2022102609351097300_ehz283-B29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/emmm.201201717","article-title":"Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes","volume":"5","author":"Soehnlein","year":"2013","journal-title":"EMBO Mol Med"},{"key":"2022102609351097300_ehz283-B30","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.114.304649","article-title":"Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis","volume":"35","author":"Drechsler","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B31","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.112.000116","article-title":"Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice","volume":"127","author":"Majmudar","year":"2013","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B32","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jacc.2010.04.066","article-title":"A new monocyte chemotactic protein-1\/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia\/reperfusion injury in mice","volume":"56","author":"Liehn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022102609351097300_ehz283-B33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjcard.2010.11.005","article-title":"Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region","volume":"107","author":"Gilbert","year":"2011","journal-title":"Am J Cardiol"},{"key":"2022102609351097300_ehz283-B34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCRESAHA.114.302426","article-title":"Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication","volume":"114","author":"D\u00f6ring","year":"2014","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.21873\/invivo.11035","article-title":"Effects of therapy with maraviroc on the carotid intima media thickness in HIV-1\/HCV co-infected patients","volume":"31","author":"Maggi","year":"2017","journal-title":"In Vivo"},{"key":"2022102609351097300_ehz283-B36","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1160\/th14-02-0139","article-title":"Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome","volume":"112","author":"Blanchet","year":"2014","journal-title":"Thromb Haemost"},{"key":"2022102609351097300_ehz283-B37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm.1898","article-title":"Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice","volume":"15","author":"Koenen","year":"2009","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B38","doi-asserted-by":"crossref","first-page":"10647","DOI":"10.1038\/s41598-018-29026-0","article-title":"Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis","volume":"8","author":"Vajen","year":"2018","journal-title":"Sci Rep"},{"key":"2022102609351097300_ehz283-B39","doi-asserted-by":"crossref","first-page":"317ra196","DOI":"10.1126\/scitranslmed.aad5330","article-title":"Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5","volume":"7","author":"Alard","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022102609351097300_ehz283-B40","first-page":"212","article-title":"The CXCL12\/CXCR4 chemokine ligand\/receptor axis in cardiovascular disease","volume":"5","author":"D\u00f6ring","year":"2014","journal-title":"Front Physiol Frontiers"},{"key":"2022102609351097300_ehz283-B41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.117.027646","article-title":"Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity: evidence from mouse and human studies","volume":"136","author":"D\u00f6ring","year":"2017","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1160\/TH17-04-0271","article-title":"Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques","volume":"118","author":"Merckelbach","year":"2018","journal-title":"Thromb Haemost"},{"key":"2022102609351097300_ehz283-B43","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/CIRCULATIONAHA.118.037953","article-title":"CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease","volume":"139","author":"D\u00f6ring","year":"2019","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B44","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/eurheartj\/ehr091","article-title":"The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels","volume":"32","author":"Mehta","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102609351097300_ehz283-B45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2018.04.067","article-title":"Blood CSF1 and CXCL12 as causal mediators of coronary artery disease","volume":"72","author":"Sjaarda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102609351097300_ehz283-B46","doi-asserted-by":"crossref","first-page":"1432.","DOI":"10.3389\/fimmu.2017.01432","article-title":"Development of novel promiscuous anti-chemokine peptibodies for treating autoimmunity and inflammation","volume":"8","author":"Abraham","year":"2017","journal-title":"Front Immunol Frontiers"},{"key":"2022102609351097300_ehz283-B47","doi-asserted-by":"crossref","first-page":"eaah6650.","DOI":"10.1126\/scitranslmed.aah6650","article-title":"Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation","volume":"9","author":"Hundelshausen von","year":"2017","journal-title":"Sci Transl Med"},{"key":"2022102609351097300_ehz283-B48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fphys.2012.00018","article-title":"T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases","volume":"3","author":"Lichtman","year":"2012","journal-title":"Front Physiol"},{"key":"2022102609351097300_ehz283-B49","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/ATVBAHA.118.307742","article-title":"2016 Jeffrey M. Hoeg award lecture","volume":"38","author":"Rouwet","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cvr\/cvx248","article-title":"Exploring immune checkpoints as potential therapeutic targets in atherosclerosis","volume":"114","author":"Kusters","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2022102609351097300_ehz283-B51","first-page":"180","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"116","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022102609351097300_ehz283-B52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/ATVBAHA.117.308611","article-title":"ATVB distinguished scientist award: how costimulatory and coinhibitory pathways shape atherosclerosis","volume":"37","author":"Ley","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/eurheartj\/ehy714","article-title":"Deficiency of the T cell regulator casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death","volume":"40","author":"Seijkens","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102609351097300_ehz283-B54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0021-9150(97)00135-4","article-title":"Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation","volume":"133","author":"de Boer","year":"1997","journal-title":"Atherosclerosis"},{"key":"2022102609351097300_ehz283-B55","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1161\/01.CIR.0000127121.16815.F1","article-title":"1\/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice","volume":"109","author":"Buono","year":"2004","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B56","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","article-title":"CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-\/-) mice","volume":"97","author":"Ma","year":"2013","journal-title":"Cardiovasc Res"},{"key":"2022102609351097300_ehz283-B58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/DDDT.S59594","article-title":"Inhibition of B7-1 (CD80) by RhuDex\u00ae reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions","volume":"8","author":"Doesch","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"2022102609351097300_ehz283-B59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijcard.2014.04.071","article-title":"Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules","volume":"174","author":"M\u00fcller","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022102609351097300_ehz283-B60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-015-0157-4","article-title":"Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis","volume":"6","author":"Meletta","year":"2016","journal-title":"EJNMMI Res"},{"key":"2022102609351097300_ehz283-B61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"2022102609351097300_ehz283-B62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"2022102609351097300_ehz283-B63","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B64","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1073\/pnas.97.13.7458","article-title":"Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice","volume":"97","author":"Sch\u00f6nbeck","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102609351097300_ehz283-B65","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1073\/pnas.97.13.7464","article-title":"Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype","volume":"97","author":"Lutgens","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102609351097300_ehz283-B66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20091293","article-title":"Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile","volume":"207","author":"Lutgens","year":"2010","journal-title":"J Exp Med"},{"key":"2022102609351097300_ehz283-B67","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1161\/01.CIR.0000103700.05109.0D","article-title":"Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty","volume":"108","author":"Cipollone","year":"2003","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B68","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/ci500631e","article-title":"Discovery of small molecule CD40-TRAF6 inhibitors","volume":"55","author":"Zarzycka","year":"2015","journal-title":"J Chem Inf Model"},{"key":"2022102609351097300_ehz283-B69","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1073\/pnas.1400419111","article-title":"Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance","volume":"111","author":"Chatzigeorgiou","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102609351097300_ehz283-B70","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","article-title":"Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis","volume":"71","author":"Seijkens","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102609351097300_ehz283-B71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ijo.2014.198","article-title":"Blocking CD40-Traf6 interactions by small molecule inhibitor 6860766 ameliorates the complications of diet induced obesity in mice","volume":"39","author":"van den Berg","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"2022102609351097300_ehz283-B72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-017-0875-9","article-title":"Toom den M, Gijbels MJJ, Boon L, Weber C, de Vries HE, Nicolaes GAF, Dijkstra CD, Kooij G, Lutgens E. Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation","volume":"14","author":"Aarts","year":"2017","journal-title":"J Neuroinflammation"},{"key":"2022102609351097300_ehz283-B73","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2018.09.008","article-title":"Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance","volume":"49","author":"Braza","year":"2018","journal-title":"Immunity"},{"key":"2022102609351097300_ehz283-B74","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2018.12.076","article-title":"Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure","volume":"279","author":"Bosch","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102609351097300_ehz283-B75","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41551-018-0221-2","article-title":"Efficacy and safety assessment of a TRAF6- targeted nanoimmunotherapy in atherosclerotic mice and non-human primates","volume":"2","author":"Lameijer","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"2022102609351097300_ehz283-B76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"O\u2019Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2022102609351097300_ehz283-B77","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/eurheartj\/ehy124","article-title":"Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques","volume":"39","author":"Tomas","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102609351097300_ehz283-B78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1084\/jem.20150900","article-title":"The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease","volume":"213","author":"Shirai","year":"2016","journal-title":"J Exp Med"},{"key":"2022102609351097300_ehz283-B79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.celrep.2015.05.046","article-title":"mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation","volume":"12","author":"Moon","year":"2015","journal-title":"Cell Rep"},{"key":"2022102609351097300_ehz283-B80","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/CIRCRESAHA.118.312804","article-title":"Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models","volume":"123","author":"Kim","year":"2018","journal-title":"Circ Res"},{"key":"2022102609351097300_ehz283-B81","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.celrep.2018.10.092","article-title":"A defective pentose phosphate pathway reduces inflammatory macrophage responses during hypercholesterolemia","volume":"25","author":"Baardman","year":"2018","journal-title":"Cell Rep"},{"key":"2022102609351097300_ehz283-B82","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu Rev Physiol"},{"key":"2022102609351097300_ehz283-B83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2016.11.018","article-title":"Hematopoietic arginase 1 deficiency results in decreased leukocytosis and increased foam cell formation but does not affect atherosclerosis","volume":"256","author":"Ren","year":"2017","journal-title":"Atherosclerosis"},{"key":"2022102609351097300_ehz283-B84","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1073\/pnas.1517820112","article-title":"Indoleamine 2, 3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development","volume":"112","author":"Cole","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102609351097300_ehz283-B85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/BJ20111275","article-title":"The mitochondrial citrate carrier: a new player in inflammation","volume":"438","author":"Infantino","year":"2011","journal-title":"Biochem J"},{"key":"2022102609351097300_ehz283-B86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11986","article-title":"Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1","volume":"496","author":"Tannahill","year":"2013","journal-title":"Nature"},{"key":"2022102609351097300_ehz283-B87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2006.05.011","article-title":"Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation","volume":"4","author":"Vats","year":"2006","journal-title":"Cell Metab"},{"key":"2022102609351097300_ehz283-B88","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"2022102609351097300_ehz283-B89","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"key":"2022102609351097300_ehz283-B90","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med"},{"key":"2022102609351097300_ehz283-B91","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"key":"2022102609351097300_ehz283-B92","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"2022102609351097300_ehz283-B93","doi-asserted-by":"crossref","first-page":"950.","DOI":"10.3389\/fimmu.2018.00950","article-title":"Activation of the regulatory T-cell\/indoleamine 2,3-dioxygenase axis reduces vascular inflammation and atherosclerosis in hyperlipidemic mice","volume":"9","author":"Forteza","year":"2018","journal-title":"Front Immunol"},{"key":"2022102609351097300_ehz283-B94","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nn.2569","article-title":"Melanocortin signaling in the CNS directly regulates circulating cholesterol","volume":"13","author":"Perez-Tilve","year":"2010","journal-title":"Nat Neurosci"},{"key":"2022102609351097300_ehz283-B95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2016.09.014","article-title":"Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease","volume":"167","author":"Finan","year":"2016","journal-title":"Cell"},{"key":"2022102609351097300_ehz283-B96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B97","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"2022102609351097300_ehz283-B98","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.118.311185","article-title":"Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation","volume":"38","author":"Rinne","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2015.10.109","article-title":"Monoglyceride lipase deficiency modulates endocannabinoid signaling and improves plaque stability in ApoE-knockout mice","volume":"244","author":"Vujic","year":"2016","journal-title":"Atherosclerosis"},{"key":"2022102609351097300_ehz283-B100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/ATVBAHA.112.300275","article-title":"Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice","volume":"33","author":"Lenglet","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B101","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2012.03.002","article-title":"At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction","volume":"33","author":"Montecucco","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2022102609351097300_ehz283-B102","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.yjmcc.2013.11.013","article-title":"Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice","volume":"66","author":"Hoyer","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"2022102609351097300_ehz283-B103","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/ATVBAHA.117.310418","article-title":"Melanocortin 1 receptor deficiency promotes atherosclerosis in apolipoprotein E-\/- mice","volume":"38","author":"Rinne","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.116.025889","article-title":"Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages","volume":"136","author":"Rinne","year":"2017","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B105","first-page":"115","article-title":"Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease","author":"He","year":"2019"},{"key":"2022102609351097300_ehz283-B106","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41586-019-0948-2","article-title":"Sleep modulates haematopoiesis and protects against atherosclerosis","volume":"566","author":"McAlpine","year":"2019","journal-title":"Nature"},{"key":"2022102609351097300_ehz283-B107","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.physiol.62.1.413","article-title":"Leptin","volume":"62","author":"Ahima","year":"2000","journal-title":"Annu Rev Physiol"},{"key":"2022102609351097300_ehz283-B108","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/35078085","article-title":"Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus","volume":"411","author":"Cowley","year":"2001","journal-title":"Nature"},{"key":"2022102609351097300_ehz283-B109","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1210\/en.2005-1209","article-title":"Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL\/6J mice lacking melanocortin-3 or -4 receptors","volume":"147","author":"Sutton","year":"2006","journal-title":"Endocrinology"},{"key":"2022102609351097300_ehz283-B110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despr\u00e9s","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102609351097300_ehz283-B111","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrendo.2015.48","article-title":"Hypothalamic innate immune reaction in obesity","volume":"11","author":"K\u00e4lin","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2022102609351097300_ehz283-B112","doi-asserted-by":"crossref","first-page":"15143.","DOI":"10.1038\/ncomms15143","article-title":"TNF\u03b1 drives mitochondrial stress in POMC neurons in obesity","volume":"8","author":"Yi","year":"2017","journal-title":"Nat Commun"},{"key":"2022102609351097300_ehz283-B113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tem.2018.03.001","article-title":"Regulation of adipose tissue metabolism by the endocannabinoid system","volume":"29","author":"van Eenige","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2022102609351097300_ehz283-B114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1421420112","article-title":"A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome","volume":"112","author":"Bowles","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102609351097300_ehz283-B115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm.3265","article-title":"Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes","volume":"19","author":"Jourdan","year":"2013","journal-title":"Nat Med"},{"key":"2022102609351097300_ehz283-B116","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1172\/JCI83626","article-title":"Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages","volume":"127","author":"Ruiz de Azua","year":"2017","journal-title":"J Clin Invest"},{"key":"2022102609351097300_ehz283-B117","doi-asserted-by":"crossref","first-page":"e000609","DOI":"10.1161\/JAHA.113.000609","article-title":"The effect of salsalate therapy on endothelial function in a broad range of subjects","volume":"3","author":"Nohria","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2022102609351097300_ehz283-B118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","article-title":"Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis","volume":"44","author":"Bernatsky","year":"2005","journal-title":"Rheumatology"},{"key":"2022102609351097300_ehz283-B119","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022102609351097300_ehz283-B120","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"2022102609351097300_ehz283-B121","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022102609351097300_ehz283-B122","doi-asserted-by":"crossref","first-page":"e004373","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2022102609351097300_ehz283-B123","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2022102609351097300_ehz283-B124","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-018-0336-8","article-title":"ApoE attenuates unresolvable inflammation by complex formation with activated C1q","volume":"2019","author":"Yin","year":"2019","journal-title":"Nat Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/48\/3937\/46640589\/eurheartj_40_48_3937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/48\/3937\/46640589\/eurheartj_40_48_3937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T09:40:47Z","timestamp":1666777247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/48\/3937\/5497815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":124,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2019,5,23]]},"published-print":{"date-parts":[[2019,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz283","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,21]]},"published":{"date-parts":[[2019,5,23]]}}}